These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23061779)

  • 1. Risk Communication and the Pharmaceutical Industry: what is the reality?
    Edwards B; Chakraborty S
    Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting the people?: risk communication and the chequered history and performance of bureaucracy.
    Hugman B
    Drug Saf; 2012 Nov; 35(11):1005-25. PubMed ID: 23061778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk perception and communication in sub-Saharan Africa.
    Dodoo A; Hugman B
    Drug Saf; 2012 Nov; 35(11):1041-52. PubMed ID: 23061780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of drug risk communications in the Philippines.
    Hartigan-Go K
    Drug Saf; 2012 Nov; 35(11):995-1004. PubMed ID: 23061777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Making Patient-focused Information Provision a Reality: One Company's Approach].
    Takemoto S
    Yakugaku Zasshi; 2018; 138(3):315-323. PubMed ID: 29503422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.
    Lem J; Younus M; Aram JA; Moosavi S; Freivogel K; Lewis A; Sobel RE
    Pharmaceut Med; 2019 Apr; 33(2):121-133. PubMed ID: 31933256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of risk communication and the role of the pharmaceutical industry.
    Chakraborty S; Bouder F
    Curr Drug Saf; 2013 Feb; 8(1):4-10. PubMed ID: 23656442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions: when the risk becomes a reality for patients.
    Cox AR; Butt TF
    Drug Saf; 2012 Nov; 35(11):977-81. PubMed ID: 23061775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-based approach to scheduling audits.
    Rönninger S; Holmes M
    PDA J Pharm Sci Technol; 2009; 63(6):575-88. PubMed ID: 20169864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.